About Us

Ichor Biologics (Ichor) is a NYC-based, pre-clinical biotechnology company that has generated a novel platform for the isolation of naturally-occurring human monoclonal antibodies (Abs) against infectious diseases. Ichor aims to utilize this platform to accelerate therapeutic development in the infectious disease space by rapidly producing Antibody-based therapeutics, which possess high safety and clinical efficacy profiles. The speed and efficacy of the platform will be utilized to produce Antibody-related intellectual property (IP) through the preclinical validation stage, which will be leveraged to establish strategic partnerships or licensing deals in order to engage industry partners, thereby providing access to clinical trial pipelines.

​